Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Nicolas Girard, Jair Bar, Pilar Garrido, Marina Chiara Garassino, Fiona McDonald, F. Mornex, Andrea Riccardo Filippi, Hans J.M. Smit, Solange Peters, John K. Field, Daniel C. Christoph, Anne Sibille, Rainer Fietkau, Vilde Drageset Haakensen, C. Chouaïd, Ben Markman, T. Jeroen N. Hiltermann, Álvaro Taus, W. Sawyer, A. Allen, Pratibha Chander, Muriel Licour, Benjamin Solomon